Suppr超能文献

骨髓中原发性骨髓纤维化伴纤维化前期与特发性血小板增多症的多组学差异。

Multi-omics differences in the bone marrow between essential thrombocythemia and prefibrotic primary myelofibrosis.

机构信息

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin, 300020, China.

Tianjin Institutes of Health Science, Tianjin, 301600, China.

出版信息

Clin Exp Med. 2024 Jul 8;24(1):154. doi: 10.1007/s10238-024-01350-y.

Abstract

Essential thrombocythemia (ET) and prefibrotic primary myelofibrosis (pre-PMF) are Philadelphia chromosome-negative myeloproliferative neoplasms. These conditions share overlapping clinical presentations; however, their prognoses differ significantly. Current morphological diagnostic methods lack reliability in subtype differentiation, underlining the need for improved diagnostics. The aim of this study was to investigate the multi-omics alterations in bone marrow biopsies of patients with ET and pre-PMF to improve our understanding of the nuanced diagnostic characteristics of both diseases. We performed proteomic analysis with 4D direct data-independent acquisition and microbiome analysis with 2bRAD-M sequencing technology to identify differential protein and microbe levels between untreated patients with ET and pre-PMF. Laboratory and multi-omics differences were observed between ET and pre-PMF, encompassing diverse pathways, such as lipid metabolism and immune response. The pre-PMF group showed an increased neutrophil-to-lymphocyte ratio and decreased high-density lipoprotein and cholesterol levels. Protein analysis revealed significantly higher CXCR2, CXCR4, and MX1 levels in pre-PMF, while APOC3, APOA4, FABP4, C5, and CFB levels were elevated in ET, with diagnostic accuracy indicated by AUC values ranging from 0.786 to 0.881. Microbiome assessment identified increased levels of Mycobacterium, Xanthobacter, and L1I39 in pre-PMF, whereas Sphingomonas, Brevibacillus, and Pseudomonas_E were significantly decreased, with AUCs for these genera ranging from 0.833 to 0.929. Our study provides preliminary insights into the proteomic and microbiome variations in the bone marrow of patients with ET and pre-PMF, identifying specific proteins and bacterial genera that warrant further investigation as potential diagnostic indicators. These observations contribute to our evolving understanding of the multi-omics variations and possible mechanisms underlying ET and pre-PMF.

摘要

原发性骨髓纤维化前期(pre-PMF)和特发性血小板增多症(ET)是两种无费城染色体阴性的骨髓增殖性肿瘤。这两种疾病的临床表现有重叠之处,但其预后有显著差异。目前的形态学诊断方法在亚型鉴别方面缺乏可靠性,因此需要改进诊断方法。本研究旨在探讨 ET 和 pre-PMF 患者骨髓活检的多组学改变,以加深对这两种疾病的细微诊断特征的理解。我们使用 4D 直接数据非依赖性采集进行蛋白质组学分析,使用 2bRAD-M 测序技术进行微生物组分析,以鉴定未经治疗的 ET 和 pre-PMF 患者之间的差异蛋白和微生物水平。在 ET 和 pre-PMF 之间观察到实验室和多组学差异,涵盖了多种途径,如脂质代谢和免疫反应。pre-PMF 组的中性粒细胞与淋巴细胞比值增加,高密度脂蛋白和胆固醇水平降低。蛋白质分析显示 pre-PMF 中 CXCR2、CXCR4 和 MX1 水平显著升高,而 ET 中 APOC3、APOA4、FABP4、C5 和 CFB 水平升高,AUC 值范围为 0.786 至 0.881,表明具有诊断准确性。微生物组评估发现 pre-PMF 中 Mycobacterium、Xanthobacter 和 L1I39 的水平增加,而 Sphingomonas、Brevibacillus 和 Pseudomonas_E 的水平显著降低,这些属的 AUC 值范围为 0.833 至 0.929。本研究初步探讨了 ET 和 pre-PMF 患者骨髓的蛋白质组学和微生物组学变化,确定了一些具有特异性的蛋白质和细菌属,这些蛋白质和细菌属值得进一步研究,作为潜在的诊断指标。这些观察结果有助于我们深入了解 ET 和 pre-PMF 的多组学变化及其潜在机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fec/11228008/d400aef08092/10238_2024_1350_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验